EP3720470A4 - Mutéines d'il-2 et leurs utilisations - Google Patents
Mutéines d'il-2 et leurs utilisations Download PDFInfo
- Publication number
- EP3720470A4 EP3720470A4 EP18887098.4A EP18887098A EP3720470A4 EP 3720470 A4 EP3720470 A4 EP 3720470A4 EP 18887098 A EP18887098 A EP 18887098A EP 3720470 A4 EP3720470 A4 EP 3720470A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- muteins
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101150083678 IL2 gene Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762595357P | 2017-12-06 | 2017-12-06 | |
US201862675972P | 2018-05-24 | 2018-05-24 | |
US201862721644P | 2018-08-23 | 2018-08-23 | |
US16/109,875 US10174091B1 (en) | 2017-12-06 | 2018-08-23 | IL-2 muteins |
US16/109,897 US10174092B1 (en) | 2017-12-06 | 2018-08-23 | IL-2 muteins |
PCT/US2018/062808 WO2019112854A1 (fr) | 2017-12-06 | 2018-11-28 | Mutéines d'il-2 et leurs utilisations |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3720470A1 EP3720470A1 (fr) | 2020-10-14 |
EP3720470A4 true EP3720470A4 (fr) | 2021-09-15 |
Family
ID=66751187
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP18887098.4A Pending EP3720470A4 (fr) | 2017-12-06 | 2018-11-28 | Mutéines d'il-2 et leurs utilisations |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP3720470A4 (fr) |
JP (1) | JP7250790B2 (fr) |
KR (2) | KR20200097275A (fr) |
CN (1) | CN111432831A (fr) |
AU (1) | AU2018378078A1 (fr) |
BR (1) | BR112020011343A2 (fr) |
CA (1) | CA3083941A1 (fr) |
IL (1) | IL274844A (fr) |
MX (1) | MX2020005208A (fr) |
SG (1) | SG11202003965VA (fr) |
WO (1) | WO2019112854A1 (fr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018170288A1 (fr) | 2017-03-15 | 2018-09-20 | Pandion Therapeutics, Inc. | Immunotolérance ciblée |
BR112019024127A2 (pt) | 2017-05-24 | 2020-06-23 | Pandion Therapeutics, Inc. | Imunotolerância alvejada |
US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
KR20220035333A (ko) | 2019-05-20 | 2022-03-22 | 팬디온 오퍼레이션스, 인코포레이티드 | Madcam 표적 면역관용 |
EP4017595A4 (fr) * | 2019-08-19 | 2023-12-20 | Pandion Operations, Inc. | Immunotolérance ciblée avec un agoniste de pd-1 |
CN114853874A (zh) * | 2019-09-10 | 2022-08-05 | 中国医学科学院北京协和医院 | 靶向调节t细胞的长效白介素-2及其在治疗自身免疫病中的应用 |
CA3157859A1 (fr) | 2019-10-15 | 2021-04-22 | Modernatx, Inc. | Arnm codant des polypeptides de modulation immunitaire et leurs utilisations |
CN112358540A (zh) * | 2020-11-03 | 2021-02-12 | 安徽环球基因科技有限公司 | 一种重组il2在毕赤酵母中的生产方法 |
TW202345889A (zh) * | 2022-03-03 | 2023-12-01 | 大陸商海南先聲藥業有限公司 | IL2突變體-抗體Fc嵌段融合蛋白的藥物組合物及其應用 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1007907B (zh) * | 1985-04-30 | 1990-05-09 | 弗·哈夫曼-拉罗彻有限公司 | 重组人类白细胞介素-2的提纯 |
WO2005007121A2 (fr) * | 2003-07-18 | 2005-01-27 | Massachusetts Institute Of Technology | Polypeptides de l'interleukine-2(il-2) mutante |
JP6093712B2 (ja) * | 2010-12-22 | 2017-03-08 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | インターロイキン2のスーパーアゴニストおよびアンタゴニスト |
WO2012164021A1 (fr) * | 2011-05-31 | 2012-12-06 | Novo Nordisk A/S | Epitopes de il-21 et ligands de il-21 |
US9580486B2 (en) * | 2013-03-14 | 2017-02-28 | Amgen Inc. | Interleukin-2 muteins for the expansion of T-regulatory cells |
MX2017000821A (es) * | 2014-07-21 | 2017-08-18 | Delinia Inc | Moleculas que activan selectivamente celulas t reguladoras para el tratamiento de enfermedades autoinmunes. |
KR20180133198A (ko) * | 2016-05-04 | 2018-12-13 | 암젠 인크 | T-조절 세포의 증식을 위한 인터류킨-2 뮤테인 |
WO2018184965A1 (fr) * | 2017-04-03 | 2018-10-11 | F. Hoffmann-La Roche Ag | Immunoconjugués d'il-2 avec un anticorps bispécifique anti-pd-1 et tim-3 |
BR112019024127A2 (pt) * | 2017-05-24 | 2020-06-23 | Pandion Therapeutics, Inc. | Imunotolerância alvejada |
EP3720871A4 (fr) * | 2017-12-06 | 2021-09-15 | Pandion Operations, Inc. | Immunotolérance ciblée |
-
2018
- 2018-11-28 KR KR1020207017255A patent/KR20200097275A/ko not_active Application Discontinuation
- 2018-11-28 CN CN201880077653.6A patent/CN111432831A/zh active Pending
- 2018-11-28 MX MX2020005208A patent/MX2020005208A/es unknown
- 2018-11-28 WO PCT/US2018/062808 patent/WO2019112854A1/fr unknown
- 2018-11-28 JP JP2020530653A patent/JP7250790B2/ja active Active
- 2018-11-28 EP EP18887098.4A patent/EP3720470A4/fr active Pending
- 2018-11-28 KR KR1020247008135A patent/KR20240039201A/ko active Application Filing
- 2018-11-28 BR BR112020011343-3A patent/BR112020011343A2/pt unknown
- 2018-11-28 AU AU2018378078A patent/AU2018378078A1/en active Pending
- 2018-11-28 CA CA3083941A patent/CA3083941A1/fr active Pending
- 2018-11-28 SG SG11202003965VA patent/SG11202003965VA/en unknown
-
2020
- 2020-05-21 IL IL274844A patent/IL274844A/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA3083941A1 (fr) | 2019-06-13 |
AU2018378078A1 (en) | 2020-06-18 |
BR112020011343A2 (pt) | 2020-11-17 |
EP3720470A1 (fr) | 2020-10-14 |
KR20200097275A (ko) | 2020-08-18 |
KR20240039201A (ko) | 2024-03-26 |
JP7250790B2 (ja) | 2023-04-03 |
MX2020005208A (es) | 2020-08-20 |
IL274844A (en) | 2020-07-30 |
JP2021507690A (ja) | 2021-02-25 |
WO2019112854A1 (fr) | 2019-06-13 |
SG11202003965VA (en) | 2020-06-29 |
CN111432831A (zh) | 2020-07-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3720470A4 (fr) | Mutéines d'il-2 et leurs utilisations | |
EP3681888A4 (fr) | Composés de pyrazolopyrimidinone et leurs utilisations | |
EP3720502A4 (fr) | Produits cytobiologiques et leurs utilisations thérapeutiques | |
EP3733693A4 (fr) | Variant d'il-2 | |
EP3453401A4 (fr) | Combinaison d'interleukine et utilisation de celle-ci | |
EP3758778A4 (fr) | Dispositifs médicaux et leurs utilisations | |
EP3841096A4 (fr) | Dérivés de pyridinylméthylènepipéridine et leurs utilisations | |
EP3511407A4 (fr) | Christensenella intestinihominis et son application | |
EP3902530A4 (fr) | Nanovaccins polymères et leurs utilisations | |
EP3638251A4 (fr) | Formulations de gel de bisphosphocine et leurs utilisations | |
EP3700934A4 (fr) | Composés et utilisations de ces composés | |
EP3687501A4 (fr) | Formulations d'iniparib et leurs utilisations | |
EP3808357A4 (fr) | Composition et ses applications | |
EP3762364A4 (fr) | Dérivés de pyrrolidineamide et leurs utilisations | |
EP3691629A4 (fr) | Formulations nutriment-spores et leurs utilisations | |
EP3730565A4 (fr) | Structure multicouche et ses utilisations | |
EP3683303A4 (fr) | Megamonas funiformis et ses applications | |
EP3856755A4 (fr) | Dérivés de terpinoïdes et leurs utilisations | |
EP3746077A4 (fr) | Formulations parentérales et leurs utilisations | |
EP3665191A4 (fr) | Tcr de braf spécifiques et utilisations associées | |
EP3689887A4 (fr) | Composition et dispositif électroluminescent utilisant celui-ci | |
EP3729351A4 (fr) | Chaînes de blocs rapides et résilientes à la partition | |
EP3684796A4 (fr) | Polypeptides régulateurs de succinate et utilisation associée | |
EP3635324A4 (fr) | Compositions de congélation inverse et utilisation de celles-ci | |
EP3611181A4 (fr) | Polypeptide ciblant atp1a1 et utilisation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20200605 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: VISWESWARAIAH, JYOTHSNA Inventor name: SAMPSON, ERIK ROBERT Inventor name: OTIPOBY, KEVIN LEWIS Inventor name: VINEY, JOANNE L. Inventor name: HIGGINSON-SCOTT, NATHAN |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: PANDION OPERATIONS, INC. |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40039617 Country of ref document: HK |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20210813 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 37/06 20060101ALI20210809BHEP Ipc: A61P 37/04 20060101ALI20210809BHEP Ipc: A61P 37/02 20060101ALI20210809BHEP Ipc: A61P 29/00 20060101ALI20210809BHEP Ipc: A61K 47/68 20170101ALI20210809BHEP Ipc: A61K 38/20 20060101AFI20210809BHEP |